Video that reads 'TIME IS OF THE ESSENCE EVERY DAY COUNTS 5-YEAR SURVIVAL RATE FOR SCLC IS 7%* Footnote: *Based on data from SEER 2010-2016 Reference: Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2017. National Cancer Institute. https://seer.cancer.gov/csr/1975_2017/. Accessed August 1, 2021. ~75% OR MORE OF PATIENTS WITH SCLC RELAPSE* Footnote: *~75% of patients with locally advanced disease, and >90% of patients with metastatic disease progress within 2 years of treatment. Reference: Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nat Rev Dis Primers. 2021;7(1):3. doi:10.1038/s41572-020-00235-0 ONLY 70% RECEIVED 2L TREATMENT1,2* Footnote: *Pooled analysis from Jazz Market Research in a total of 224 US based oncologists that treat SCLC. Research recruitment timeframe was April-May 2020 and 2021.1,2 References: 1. Data on file. LUR-2020-026. Palo Alto, CA: Jazz Pharmaceuticals, Inc. 2. Data on file. LUR-2020-054. Palo Alto, CA: Jazz Pharmaceuticals, Inc. THE TIME IS NOW TO FOCUS ON THE UNMET NEEDS OF SCLC'

Approximately 70% of patients are extensive-stage at diagnosis1

The recalcitrant cancer2

The 5-year survival rate for patients diagnosed with SCLC is less than 7%.* Timely intervention at the first sign of relapse may help to improve outcomes.3-5

UNDERSTANDING SCLC

►
Symptomatic at presentation4

At the time of first diagnosis,
most SCLC patients present
with bulky tumors and/or distant metastases.1,4

DIAGNOSIS AND PRESENTATION

►
Development of an appropriate long-term treatment strategy

Relapse is likely in patients with SCLC. Taking into account the poor outcome in the majority of patients with SCLC, honest conversations about prognosis and goals of therapy should take place early on. Creating a treatment plan can help patients who relapse.4

STAGING AND 1L TREATMENT

►
Plan ahead for rapid progression4

Although patients with SCLC are highly responsive to initial treatment, most patients relapse with relatively resistant disease, leading to poor prognosis.4,6,7 Early planning for second-line therapy is therefore advisable.4

RELAPSED SCLC AND 2L TREATMENT

►

~75% or more of patients with SCLC relapse.4,†
For patients with SCLC, the time is now.

SCLC=small cell lung cancer.

*SEER data based on follow-up of patients from 2010-2016, and into 2017.3

†~75% of patients with locally advanced disease and >90% of patients with metastatic disease progress within 2 years of treatment.4

    REFERENCES:
  1. Huber RM, Tufman A. Update on small cell lung cancer management. Breathe. 2012;8(4):315-330.
  2. Oronsky B, Reid TR, Oronsky A, Carter CA. What's new in SCLC? A review. Neoplasia. 2017;19(10):842-847.
  3. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2017. National Cancer Institute. https://seer.cancer.gov/csr/1975_2017/. Accessed August 9, 2021.
  4. Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nat Rev Dis Primers. 2021;7(1):3. doi:10.1038/s41572-020-00235-0
  5. Glatzer M, Rittmeyer A, Müller J, et al. Treatment of limited disease small cell lung cancer: the multidisciplinary team. Eur Respir J. 2017;50(2):1700422. doi:10.1183/13993003.00422-2017
  6. Cortinovis D, Bidoli P, Canova S, et al. Novel cytotoxic chemotherapies in small cell lung carcinoma. Cancers. 2021;13:1152. doi:10.3390/cancers13051152
  7. Byers LA, Rudin CM. Small cell lung cancer: where do we go from here? Cancer. 2015;121(5):664-672.